Celltrion, Inc.

KOSE:A068270 Stock Report

Market Cap: ₩36.4t

Celltrion Valuation

Is A068270 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A068270 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A068270 (₩175600) is trading below our estimate of fair value (₩187157.49)

Significantly Below Fair Value: A068270 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A068270?

Key metric: As A068270 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A068270. This is calculated by dividing A068270's market cap by their current revenue.
What is A068270's PS Ratio?
PS Ratio12.6x
Sales₩2.88t
Market Cap₩36.45t

Price to Sales Ratio vs Peers

How does A068270's PS Ratio compare to its peers?

The above table shows the PS ratio for A068270 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18x
A145020 Hugel
8.5x17.6%₩2.9t
A214450 PharmaResearch
7x24.3%₩2.1t
A007390 NatureCellLtd
55.4xn/a₩1.6t
A006280 GC Biopharma
1x9.0%₩1.6t
A068270 Celltrion
12.6x25.4%₩36.4t

Price-To-Sales vs Peers: A068270 is good value based on its Price-To-Sales Ratio (12.6x) compared to the peer average (18x).

Price to Sales Ratio vs Industry

How does A068270's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 CompaniesPrice / SalesEstimated GrowthMarket Cap
A006280 GC Biopharma
1x9.0%US$1.11b
A096530 Seegene
2.7x15.7%US$764.41m
A086900 Medy-Tox
3.5x12.5%US$619.60m
A005250 Green Cross Holdings
0.3xn/aUS$480.13m
A068270 12.6xIndustry Avg. 8.8xNo. of Companies26PS01632486480+
26 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A068270 is expensive based on its Price-To-Sales Ratio (12.6x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A068270's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A068270 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.6x
Fair PS Ratio11.3x

Price-To-Sales vs Fair Ratio: A068270 is expensive based on its Price-To-Sales Ratio (12.6x) compared to the estimated Fair Price-To-Sales Ratio (11.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A068270 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩175,600.00
₩245,800.00
+40.0%
13.2%₩300,000.00₩160,000.00n/a20
Nov ’25₩181,100.00
₩247,684.21
+36.8%
14.3%₩310,000.00₩150,000.00n/a19
Oct ’25₩195,400.00
₩248,736.84
+27.3%
13.3%₩310,000.00₩150,000.00n/a19
Sep ’25₩203,000.00
₩248,000.00
+22.2%
14.0%₩310,000.00₩150,000.00n/a19
Aug ’25₩200,000.00
₩239,500.00
+19.8%
14.6%₩300,000.00₩150,000.00n/a16
Jul ’25₩184,100.00
₩234,235.29
+27.2%
14.6%₩300,000.00₩150,000.00n/a17
Jun ’25₩176,200.00
₩231,882.35
+31.6%
12.5%₩300,000.00₩172,000.00n/a17
May ’25₩189,000.00
₩230,117.65
+21.8%
13.1%₩300,000.00₩172,000.00n/a17
Apr ’25₩188,100.00
₩221,117.65
+17.6%
13.9%₩300,000.00₩159,000.00n/a17
Mar ’25₩179,700.00
₩218,687.50
+21.7%
14.1%₩300,000.00₩159,000.00n/a16
Feb ’25₩178,700.00
₩222,666.67
+24.6%
12.4%₩300,000.00₩180,000.00n/a15
Jan ’25₩201,500.00
₩215,277.78
+6.8%
10.7%₩300,000.00₩180,000.00n/a18
Dec ’24₩163,100.00
₩216,944.44
+33.0%
10.9%₩300,000.00₩180,000.00n/a18
Nov ’24₩149,400.00
₩215,312.50
+44.1%
9.6%₩280,000.00₩180,000.00₩181,100.0016
Oct ’24₩139,200.00
₩210,294.12
+51.1%
13.5%₩280,000.00₩130,000.00₩195,400.0017
Sep ’24₩143,900.00
₩211,277.78
+46.8%
13.2%₩280,000.00₩130,000.00₩203,000.0018
Aug ’24₩151,000.00
₩216,352.94
+43.3%
13.4%₩280,000.00₩130,000.00₩200,000.0017
Jul ’24₩152,900.00
₩220,176.47
+44.0%
13.4%₩280,000.00₩130,000.00₩184,100.0017
Jun ’24₩175,400.00
₩219,098.29
+24.9%
13.0%₩280,000.00₩130,000.00₩176,200.0018
May ’24₩160,600.00
₩214,610.58
+33.6%
15.3%₩300,000.00₩130,000.00₩189,000.0016
Apr ’24₩149,800.00
₩217,985.58
+45.5%
16.6%₩300,000.00₩130,000.00₩188,100.0016
Mar ’24₩145,200.00
₩227,048.09
+56.4%
16.1%₩300,000.00₩144,231.00₩179,700.0016
Feb ’24₩169,800.00
₩228,851.30
+34.8%
16.2%₩300,000.00₩144,231.00₩178,700.0015
Jan ’24₩160,500.00
₩218,895.12
+36.4%
17.7%₩278,846.15₩129,437.50₩201,500.0016
Dec ’23₩171,634.62
₩216,602.56
+26.2%
17.8%₩278,846.15₩134,615.38₩163,100.0015
Nov ’23₩178,846.15
₩207,371.79
+15.9%
19.9%₩259,615.38₩125,000.00₩149,400.0012

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

J2KBIO

₩55.1b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,650.00

7D

1.7%

1Y

n/a

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩265,000.00

7D

-1.3%

1Y

69.8%

Medy-Tox

₩869.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩129,100.00

7D

4.7%

1Y

-41.2%